Achieving U.S. Food and Drug Administration priority review status for its New Drug Application, Gilead Sciences Inc. recently made strides towards realizing an investigational, fixed-dose product combining several drugs to address HIV-1 infection. Read More »
Regional Cancer Care Associates (RCCA) recently announced its attainment of accreditation by URAC, a leading nonprofit health care benchmark group, as a Specialty Pharmacy in Hackensack, New Jersey. Read More »
Award-winning, Arizona-based Avella Specialty Pharmacy recently launched an e-commerce platform to simplify orders for compounded products — featuring user-friendly, secure web access and streamlining ophthalmologists’ online tasks. Read More »
Health care investment firm Ampersand Capital Partners recently divested its former portfolio firm Roadrunner Pharmacy in a deal transferring Roadrunner to Vets First Choice after five years of supported growth in revenue and EBITDA. Read More »
Express Scripts, one of the largest pharmacy benefit managers (PBMs) in the country, has announced the expansion of a pilot program that limits opioid prescriptions to seven days without prior authorization. Read More »
Innovus Pharmaceuticals has ordered 220,000 units of FlutiCare, putting the drug on pace to meet its planned launch for the fourth quarter of 2017. Read More »
Imprimis Pharmaceuticals Inc. recently released a statement after the MedWatch notification put forth by the U.S. Food and Drug Administration. Read More »
Presenting a quantum leap in telemedicine, Scottsdale, Arizona-based GlobalMed recently released its award-winning branded eNcounter platform, designed to streamline clinical and at-home care and even geared for interoperability with wearable devices, ensuring data based outcomes. Read More »
AbbVie's once-daily treatment for chronic hepatitis C virus (HCV) infection, Mavyret, has been approved by the U.S. Food and Drug Administration. Read More »
La Jolla Pharmaceutical Co. recently initiated an expanded access program (EAP) in the United States for its investigational drug LJPC-501. Read More »
AstraZeneca and Acerta Pharma's treatment for patients with mantle cell lymphoma who have received at least one prior therapy was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration. Read More »
Pfizer Inc.'s proposed dose of tofacitinib for the treatment of adult patients with active psoriatic arthritis received recommendation for approval by the U.S. Food and Drug Administration’s Arthritis Advisory Committee via a 10-1 vote. Read More »
The Center for Pharmacy Practice Accreditation has awarded PANTHERx Specialty Pharmacy a practice accreditation. Read More »
International pharmaceutical provider Mylan recently obtained what it called tentative approval of its New Drug Application for an antiretroviral formula to circulate as a preferred treatment for HIV/AIDS patients in developing nations. Read More »
New York University Langone Medical Center has released results of an Alzheimer’s disease study that shows combining a specific care management program with commonly prescribed drugs multiplies the drug’s ability to improve daily function by roughly 7.5 times and stalls some of the disease’s effects. Read More »
National Association of Specialty Pharmacy Executive Director Sheila Arquette recently responded to a report on direct and indirect remuneration fees commissioned by the Pharmaceutical Care Management Association. Read More »
Moleculin Biotech Inc. recently released comments regarding recent FDA approvals for new drugs that treat acute myeloid leukemia. Read More »
Mitsubishi Tanabe Pharma America Inc. of New Jersey has reported that Radicava (edaravone), an intravenous therapy for adults with amyotrophic lateral sclerosis (ALS), is now available in the U.S. Read More »
A trial treatment for peanut allergy has attracted attention in the media, with a recent Washington state publication highlighting California-based Aimmune Therapeutics Inc.’s “AR101” as a potential immunotherapy with the ability to impact allergen-specific T cells. Read More »
The U.S. Food and Drug Administration recently accepted Genentech’s supplemental New Drug Application for Zelboraf (vemurafenib) — including breakthrough therapy designation — to address a form of Erdheim-Chester disease, a rare blood disorder. Read More »
Alerts Sign-up
